With a deep understanding of molecular mechanisms and disease biology, we have successfully developed a series of proprietary technology platforms for different targets, mechanisms of action and modes, including LeadsBody™ platform (CD3 T-cell engager platform) and X-body™ platform (4-1BB engager platform), as well as other bispecific antibody and antibody fusion protein platforms.
LeadsBody™
X-body™
LeadsBody™
To achieve an optimal balance between safety and efficacy of T-cell engagers, we have developed a proprietary LeadsBody™ platform (CD3 Tcell engager platform) capable of facilitating diverse modifications to the molecular designs of CD3-targeted bispecific antibodies. These key modifications include variable expression levels in binding to tumor-associated antigens (TAA), fine-tuning CD3 affinity with differentiated profiles of cytokine release, conditional T-cell redirecting and activation mechanisms within tumor microenvironments, and differing spatial structures. By harnessing this platform technology, our multiple CD3-targeted bispecific T-cell engaging antibodies for treating solid tumors and hematologic malignancies, such as LBL-034 and LBL-033, have demonstrated promising antitumor effects and favorable safety profiles both in preclinical and clinical studies.
We believe our LeadsBody™ platform possesses these significant advantages: • optimized proportions and affinities of TAA and CD3 binding domains directing the action of T-cell engagers to the tumor site, minimizing off-target toxicity; • structural optimizations inducing effective killing of target cells by T cells while reducing cytokine secretion; and • both in vitro and in vivo studies, T-cell engagers exhibited durable antitumor effects with less T-cell exhaustion induction.
X-body™
Our X-body™ platform (4-1BB engager platform) leverages advanced antibody engineering technology to create differentiated bispecific antibodies in a 2:2 format with high yield, high purity and excellent druggability. We have developed a method to enhance the yield and stability of the scFv structure, which is applicable to most antibodies, allowing rapid conversion of Fab to scFv.
X-body™ platform applies advanced antibody engineering technology to balance the affinity between TAA and 4-1BB, facilitating the crosslinking and activation of the 4-1BB receptor only when binding to TAA at tumor sites, thereby localizing 4-1BB activation in TAA expressing tumor microenvironment. Such unique molecular structure is able to bolster the immune response within the tumor microenvironment, while mitigating the risk of systemic toxicities. Oun core product LBL-024 was developed based on our X-body™ platform.
